Sandbox Turky2
| Column heading 1 | Column heading 2 | Column heading 3 |
|---|---|---|
| Row heading 1 | Cell 2 | Cell 3 |
| Row heading A | Cell B | Cell C |
| Pathogen | Immunocompetent patients | Immunocompromised patients |
|---|---|---|
| Shigella species | TMP-SMZ, 160 and 800 mg, respectively (pediatric dose, 5 and 25 mg/kg, respectively) b.i.d. 3 3 d (if susceptiblea ) or fluoroquinoloneb (e.g., 300 mg ofloxacin, 400 mg norfloxacin [186], or 500 mg ciprofloxacin b.i.d. 3 3 d); nalidixic acid, 55 mg/kg/d (pediatric) or 1 g/d (adults) 3 5 d [220] or ceftriaxone azithromycin [121] | 3 7–10 d |
| Non-typhi species of Salmonella | Not recommended routinely (E-I) [59,60], but if severe or patient is !6 mo or 150 y old or has prostheses, valvular heart disease, severe atherosclerosis, malignancy, or uremia, TMP-SMZ (if susceptible) or fluoroquinolone as above, b.i.d. 3 5–7 d; ceftriaxone, 100 mg/kg/d in 1 or 2 divided doses | 14 d (or longer if relapsing) |